Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Comparing pharmacokinetic and pharmacodynamic profiles in female rats orally exposed to lovastatin by gavage versus diet.

Martín-Jiménez T, Lindeblad M, Kapetanovic IM, Chen Y, Lyubimov A.

Chem Biol Interact. 2008 Jan 30;171(2):142-51.

PMID:
17854789
2.

Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.

Kapetanovic IM, Krishnaraj R, Martin-Jimenez T, Yuan L, van Breemen RB, Lyubimov A.

Chem Biol Interact. 2006 Dec 1;164(1-2):68-75.

PMID:
17027946
3.

Comparison of pharmacokinetic and pharmacodynamic profiles of aspirin following oral gavage and diet dosing in rats.

Kapetanovic IM, Bauer KS, Tessier DM, Lindeblad MO, Zakharov AD, Lubet R, Lyubimov A.

Chem Biol Interact. 2009 May 15;179(2-3):233-9. doi: 10.1016/j.cbi.2008.10.008.

PMID:
18992230
4.

Distribution of lovastatin to bone and its effect on bone turnover in rats.

Jadhav SB, Narayana Murthy PS, Singh MM, Jain GK.

J Pharm Pharmacol. 2006 Nov;58(11):1451-8.

PMID:
17132207
5.

Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations.

Gutierrez GE, Lalka D, Garrett IR, Rossini G, Mundy GR.

Osteoporos Int. 2006;17(7):1033-42.

PMID:
16758140
6.

Effects of lovastatin on the pharmacokinetics of nicardipine in rats.

Chung JW, Yang SH, Choi JS.

Biopharm Drug Dispos. 2010 Oct;31(7):436-41. doi: 10.1002/bdd.721.

PMID:
20824619
7.

Novel extended-release formulation of lovastatin by one-step melt granulation: in vitro and in vivo evaluation.

Ochoa L, Igartua M, Hernández RM, Gascón AR, Solinis MA, Pedraz JL.

Eur J Pharm Biopharm. 2011 Feb;77(2):306-12. doi: 10.1016/j.ejpb.2010.11.024.

PMID:
21172434
8.

[The effect of hypolipemic treatment on the pharmacokinetics of propranolol].

Sterna R.

Ann Acad Med Stetin. 1997;43:67-77. Polish.

PMID:
9471924
9.

Pharmacokinetic profile of armodafinil in healthy subjects: pooled analysis of data from three randomized studies.

Darwish M, Kirby M, Hellriegel ET, Yang R, Robertson P Jr.

Clin Drug Investig. 2009;29(2):87-100. doi: 10.2165/0044011-200929020-00003.

PMID:
19133704
10.

Comparative pharmacokinetics of lovastatin extended-release tablets and lovastatin immediate-release tablets in humans.

Sun JX, Niecestro R, Phillips G, Shen J, Lukacsko P, Friedhoff L.

J Clin Pharmacol. 2002 Feb;42(2):198-204.

PMID:
11831543
11.
12.

First human exposure to exogenous single-dose oral estetrol in early postmenopausal women.

Visser M, Holinka CF, Coelingh Bennink HJ.

Climacteric. 2008;11 Suppl 1:31-40. doi: 10.1080/13697130802056511.

PMID:
18464021
13.

Development and pharmacology of fluvastatin.

Jokubaitis LA.

Br J Clin Pract Suppl. 1994 Dec;(77):11-5. Update in: Br J Clin Pract Suppl. 1996 Jan;77A:11-5.

PMID:
19489169
14.

Pharmacokinetics and bioequivalence study of two tablet formulations of lovastatin in healthy volunteers.

Mignini F, Tomassoni D, Streccioni V, Traini E, Amenta F.

Clin Exp Hypertens. 2008 Feb;30(2):95-108. doi: 10.1080/10641960801944249.

PMID:
18293165
15.

Effects of rutin on lipid profile in hypercholesterolaemic rats.

Ziaee A, Zamansoltani F, Nassiri-Asl M, Abbasi E.

Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):253-8. doi: 10.1111/j.1742-7843.2008.00368.x.

16.

Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.

Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ.

Cancer Chemother Pharmacol. 2006 Jan;57(2):155-64. Erratum in: Cancer Chemother Pharmacol. 2007 Mar;59(4):559.

PMID:
16133537
17.
18.

Pharmacokinetics of orally administered single- and multiple-dose olopatadine in healthy Chinese subjects: an open-label study.

Chu NN, Chen WL, Xu HR, Li XN.

Clin Drug Investig. 2009;29(7):451-7. doi: 10.2165/00044011-200929070-00003.

PMID:
19499962
19.

Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model.

Coelingh Bennink HJ, Heegaard AM, Visser M, Holinka CF, Christiansen C.

Climacteric. 2008;11 Suppl 1:2-14. doi: 10.1080/13697130701798692.

PMID:
18464016
20.

Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo.

Ciosek CP Jr, Magnin DR, Harrity TW, Logan JV, Dickson JK Jr, Gordon EM, Hamilton KA, Jolibois KG, Kunselman LK, Lawrence RM, et al.

J Biol Chem. 1993 Nov 25;268(33):24832-7.

Supplemental Content

Support Center